Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

ChemMedChem

Volumn 2, Issue 1, 2007, Pages 58-61

  Pan, Zhengying ^a   Scheerens, Heleen ^a   Li, Shyr Jiann ^a   Schultz, Brian E ^a   Sprengeler, Paul A ^a   Burrill, L Chuck ^a   Mendonca, Rohan V ^a   Sweeney, Michael D ^a   Scott, Keana C K ^b   Grothaus, Paul G ^a   Jeffery, Douglas A ^a   Spoerke, Jill M ^a   Honigberg, Lee A ^a   Young, Peter R ^a   Dalrymple, Stacie A ^a   Palmer, James T ^a  

^a Celera Genomics ^*  (United States)

^b Informatics Research   (United States)

Author keywords

Biological activity; Drug design; Enzymes; Medicinal chemistry; Structural bioinformatics

Indexed keywords

ADENOSINE TRIPHOSPHATE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTIRHEUMATIC AGENT; OLIGOPEPTIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BINDING SITE; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; METABOLISM; MOLECULAR GENETICS; RHEUMATOID ARTHRITIS; RODENT; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BINDING SITES; DISEASE MODELS, ANIMAL; DRUG DESIGN; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RODENTIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38049084406     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200600221     Document Type: Article

References (23)

1. C. M. Lewis, C. Broussard, M. J. Czar, P. L. Schwartzberg, Curr. Opin. Immunol. 2001, 13, 317.
2. J. B. Petro, S. M. Jamshedur Rahman, D. W. Ballard, W. N. Khan, J. Exp. Med. 2000, 191, 1745.
3. J. E. Heinonen, C. I. E. Smith, B. E. Nore, FEBS Lett. 2002, 527, 274.
4. S. Mahajan, S. Ghosh, E. A. Sudbeck, Y. Zheng, S. Downs, M. Hupke, F. M. Uckun, J. Biol. Chem. 1999, 274, 9587.
5. a) D. W. Fry, A. J. Bridges, W. A. Denny, A. Doherty, K. D. Greis, J. L. Hicks, K. E. Hook, P. R. Keller, W. R. Leopold, J. A. Loo, D. J. McNamara, J. M. Nelson, V. Sherwood, J. B. Smaill, S. Trumpp-Kallmeyer, E. M. Dobrusin, Proc. Natl. Acad. Sci. USA 1998, 95, 12 022-12 027;
6. b) M. S. Cohen, C. Zhang, K. M. Shokat, J. Tauton, Science 2005, 308, 1318.
7. A similar compound was reported as a potent Lck inhibitor: L. D. Arnold, D. J. Calderwood, R. W. Dixon, D. N. Johnson, J. S. Kamens, R. Munschauer, P. Rafferty, S. E. Ratnofsky, Bioorg. Med. Chem. Lett. 2000, 10, 2167.
8. M. A. Fabian, W. H. Biggs III, D. K. Treiber, C. E. Atteridge, M. D. Azimioara, M. G. Benedetti, T. A. Carter, P. Ciceri, P. T. Edeen, M. Floyd, J. M. Ford, M. Galvin, J. L. Gerlach, R. M. Grotzfeld, S. Herrgard, D. E. Insko, M. A. Insko, A. G. Lai, J.-M. Lelias, S. A. Mehta, Z. V. Milanov, A. M. Velasco, L. M. Wodicka, H. K. Patel, P. P. Zarrinkar, D. J. Lockhart, Nat. Biotechnol. 2005, 23, 329.
9. Y. Liu, A. Bishop, L. Witucki, B. Kraybill, E. Shimizu, J. Tsien, J. Ubersax, J. Blethrow, D. O. Morgan, K. M. Shokat, Chem. Biol. 1999, 6, 671.
10. S. V. Frye, Chem. Biol. 1999, 6, R3-R7.
11. C. Mao, M. Zhou, F. M. Uckun, J. Biol. Chem. 2001, 276, 41 435.
12. X. Zhu, K. A. Morgenstern, Structure 1999, 7, 651.
13. D. W. Fry, Pharmacol. Ther. 2002, 93, 253.
14. H.-R. Tsou, E. G. Overbeek-Klumpers, W. A. Hallett, M. B. Floyd, B. D. Johnson, R. S. Michalak, R. Nilakantan, C. Discafani, J. Golas, S. K. Rabindran, R. Shen, X. Shi, Y-F. Wang, J. Upeslacis, A. Wissner, J. Med. Chem. 2005, 48, 1107.
15. Sugen and Salk Institute, http://198.202.68.14/human/kinome/phylogeny. html.
16. J. B. Smaill, B. D. Palmer, G. W. Rewcastle, W. A. Denny, D. J. McNamara, E. M. Dobrusin, A. J. Bridges, H. Zhou, H. D. Hollis Showalter, R. Thomas Winters, W. R. Leopold, D. W. Fry, J. M. Nelson, V. Slintak, W. L. Elliot, B. J. Roberts, P. W. Vincent, S. J. Patmore, J. Med. Chem. 1999, 42, 1803.
17. Compound 4: 440 Da; Recombinant Btk kinase domain: 33,487 Da; Complex (1:1): expected 33,927 Da, observed 33,927 Da. See Supporting Information.
18. FlexStation, Molecular Devices.
19. H.-R. Tsou, N. Mamuya, B. D. Johnson, M. F. Reich, B. C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F. E. Koehn, L. M. Greenberger, Y-F. Wang, A. Wissner, J. Med. Chem. 2001, 44, 2719.
20. Z. A. Knight, K. M. Shokat, Chem. Biol. 2005, 12, 621.
21. K. S. Nandakumar, L. Svensson, R. Holmdahl, Am. J. Pathol. 2003, 163, 1827.
22. See Supporting Information for experimental data of exposure levels of compound 4.
23. J. S. Smolen, G. Steiner, Nat. Rev. Drug Discovery 2003, 2, 473.